Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
30.67 -0.70 (-2.23%) 04/07/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 30.82 +0.15 (+0.49%) 19:47 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
28.86
Day High
32.29
Open 29.52
Previous Close 31.37 31.37
Volume 4,063,800 4,063,800
Avg Vol 2,680,945 2,680,945
Stochastic %K 22.35% 22.35%
Weighted Alpha +13.93 +13.93
5-Day Change -3.90 (-11.28%) -3.90 (-11.28%)
52-Week Range 21.62 - 39.47 21.62 - 39.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,966,229
  • Shares Outstanding, K 190,189
  • Annual Sales, $ 221,900 K
  • Annual Income, $ -535,760 K
  • EBIT $ -593 M
  • EBITDA $ -587 M
  • 60-Month Beta 1.08
  • Price/Sales 29.20
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 68.40% ( -0.11%)
  • Historical Volatility 57.47%
  • IV Percentile 60%
  • IV Rank 25.27%
  • IV High 151.63% on 11/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 4,125
  • Volume Avg (30-Day) 3,136
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 92,319
  • Open Int (30-Day) 99,628

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.90
  • Number of Estimates 7
  • High Estimate -0.72
  • Low Estimate -1.25
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -1,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.86 +6.27%
on 04/07/25
Period Open: 31.57
37.94 -19.16%
on 03/24/25
-0.90 (-2.85%)
since 03/07/25
3-Month
28.10 +9.15%
on 01/13/25
Period Open: 28.85
39.47 -22.30%
on 02/20/25
+1.82 (+6.31%)
since 01/07/25
52-Week
21.62 +41.86%
on 06/24/24
Period Open: 28.10
39.47 -22.30%
on 02/20/25
+2.57 (+9.15%)
since 04/05/24

Most Recent Stories

More News
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

BBIO : 30.67 (-2.23%)
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BBIO : 30.67 (-2.23%)
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BBIO : 30.67 (-2.23%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO : 30.67 (-2.23%)
BridgeBio Announces CFO Succession

BBIO : 30.67 (-2.23%)
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why

Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and...

NVDA : 97.64 (+3.53%)
BBIO : 30.67 (-2.23%)
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BBIO : 30.67 (-2.23%)
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BBIO : 30.67 (-2.23%)
BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 30.67 (-2.23%)
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BBIO : 30.67 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 35.78
2nd Resistance Point 34.04
1st Resistance Point 32.35
Last Price 30.67
1st Support Level 28.92
2nd Support Level 27.18
3rd Support Level 25.49

See More

52-Week High 39.47
Fibonacci 61.8% 32.65
Last Price 30.67
Fibonacci 50% 30.55
Fibonacci 38.2% 28.44
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades